Indeed, previous analyses of primary samples enrolled in HMA-based clinical trials reported that MDS patients with mutations in epigenetic modifiers such as TET2 (ref. 29) have higher rates of responses to HMA-based therapy, but others could not validate these results30. Here, TET2 is linked to myelodysplastic syndrome.